aap Implantate AG updates outlook for 2014

aap updates outlook in view of possible delays in product approvals, U.S. market entry and project deals

aap Implantate AG announces that possible delays in product approvals and registrations in Latin America, in gaining U.S. market entry for our LOQTEQ® and trauma product portfolio, and in ongoing project deals may negatively impact our sales and EBITDA forecast for 2014.

The Management assumes that sales losses directly attributable to the disposal of equity in the dental joint venture aap BM productions GmbH in the second quarter of 2014 totaling EUR 1.0 million cannot be compensated by sales in other business areas. Based on the previous sales forecast for the fiscal year 2014 of approx. EUR 35 million and taking into account the aforementioned effect original sales goal amounts to EUR 34 million.

In view of these uncertainties we see for 2014 a target corridor between EUR 30 million and EUR 34 million for full-year sales and between EUR 2.0 million and EUR 4.5 million for full-year EBITDA (previous forecast: between EUR 5.0 million and EUR 6.0 million).

The strategic focus of transforming aap Implantate AG into a leading European trauma enterprise remains our highest priority.

This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap 's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments

For further information, please contact:

distributed by